Understanding US Patent 11,591,628 for Heparin
US Patent 11,591,628 relates to methods for purifying heparin. This patent specifically details a process for removing impurities from heparin preparations, aiming to improve the quality and safety of the final product [1].
What specific impurities does this patent address?
The patent focuses on methods to reduce or remove various contaminants that can be present in heparin, including but not limited to, oversulfated chondroitin sulfate (OSCS) and other glycosaminoglycans [1]. OSCS was a significant concern due to adverse events linked to contaminated heparin in the past [2].
How does this purification method work?
The patented methods involve specific chemical or chromatographic techniques designed to selectively bind and separate unwanted compounds from the heparin matrix. These techniques aim to achieve a higher purity level than previously possible, ensuring the heparin is substantially free from harmful contaminants [1].
Why is purifying heparin important for patients?
Heparin is a critical anticoagulant medication used to prevent and treat blood clots [3]. Impurities in heparin can lead to serious adverse reactions, including anaphylaxis and thrombosis [2]. Therefore, ensuring the purity of heparin through advanced purification methods like those described in US Patent 11,591,628 is vital for patient safety and therapeutic efficacy [1][2].
When does US Patent 11,591,628 expire?
US patents generally have a term of 20 years from the date on which the application was filed. For US Patent 11,591,628, the expiration date can be determined by checking its filing history and patent term adjustment. Information on patent terms and expiry dates for various drugs and related technologies is available through resources like DrugPatentWatch.com [4].
Are there other patents related to heparin purification?
The field of heparin production and purification has seen numerous patents issued over the years, reflecting ongoing efforts to improve manufacturing processes and ensure product quality. Companies and researchers continually seek new methods to enhance heparin's safety and efficacy, leading to a landscape with multiple overlapping and sequential patents [4].
What companies are involved with heparin production and purification?
Several pharmaceutical and biotechnology companies are involved in the manufacturing and purification of heparin and its derivatives. These entities invest in research and development to secure intellectual property for their innovative processes. Identifying specific companies associated with US Patent 11,591,628 would require a detailed examination of the patent's assignees and any related legal filings.
Sources:
[1] United States Patent 11,591,628
[2] https://www.drugpatentwatch.com/news/heparin-contamination-2008
[3] https://www.drugpatentwatch.com/drugs/heparin
[4] https://www.drugpatentwatch.com/patents/search/us%20patent%2011591628